TY - JOUR
T1 - Effective Performance of the 2022 American College of Rheumatology/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in Pediatric Patients
T2 - An ARChiVe Study
AU - for the ARChiVe Investigators Network within the PedVas Initiative
AU - Cabral, David A.
AU - Bosman, Else S.
AU - McPhate, Nick
AU - Mann, Simranpreet K.
AU - Toor, Kirandeep K.
AU - Morishita, Kimberly A.
AU - Luqmani, Raashid
AU - Beresford, Michael W.
AU - Bistolarides, James
AU - Campillo, Sarah
AU - Charuvanij, Sirirat
AU - Cook, Kathryn
AU - Dancey, Paul
AU - de Guzman, Marietta
AU - Deepak, Samundeeswari
AU - Eberhard, Barbara
AU - Elder, Melissa
AU - Gagne, Samuel
AU - Harrison, Katie
AU - Huber, Adam
AU - Khan, Archana
AU - Kim, Susan
AU - Klein-Gitelman, Marisa S.
AU - Lee, Tzielan C.
AU - Li, Suzanne C.
AU - Martin, Neil
AU - McErlane, Flora
AU - Moorthy, L. Nandini
AU - Orjuela, Alvaro H.
AU - Park, Jonathan
AU - Riley, Phil
AU - Rosenberg, Alan M.
AU - Shenoi, Susan
AU - Sivaraman, Vidya
AU - Sutnga, Sodality
AU - Tanner, Tamara
AU - Tarvin, Stacey E.
AU - Twilt, Marinka
AU - Wagner-Weiner, Linda
AU - Yeung, Rae S.M.
AU - Brown, Kelly L.
N1 - Publisher Copyright:
© 2026 The Author(s). Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
PY - 2026
Y1 - 2026
N2 - Objective: To assess the 2022 American College of Rheumatology (ACR)/EULAR classification criteria for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) in children with chronic small-to-medium vessel vasculitis. Methods: A cohort of 574 patients, identified by physician's diagnosis (MD-diagnosis) in A Registry of Childhood Vasculitis, was classified by computation of registry data as having granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or eosinophilic GPA after applying (1) ACR/EULAR AAV criteria and (2) pediatric-adapted European Medicines Agency (Ped-EMA) classification algorithm (incorporating Ankara GPA criteria). Venn diagrams compared the resulting GPA and MPA cohorts with MD-diagnosis. Sensitivity and specificity of criteria for GPA were evaluated against MD-diagnosis. Fisher exact test evaluated differences in the frequencies of individual clinical features in GPA versus MPA. Results: Comparing ACR/EULAR criteria against the Ped-EMA algorithm for classifying AAV, more patients were classified as GPA or MPA (n = 396 vs 360, respectively), fewer had GPA (n = 261 vs 288, respectively), more had MPA (n = 135 vs 72, respectively), and fewer GPA cases coclassified as MPA (12% vs 28%, respectively); there were more differences between GPA and MPA in Pediatric Vasculitis Activity Score–defined clinical features (n = 14 vs 10, respectively). When classifying GPA by ACR/EULAR or Ankara criteria, sensitivity (74.5% vs 72.1%, respectively) was comparable, and specificity for ACR/EULAR criteria (93.9% vs 79.9%, respectively) was improved. Conclusion: The 2022 ACR/EULAR classification criteria for AAV perform at least as well as previous pediatric criteria and provide categorical MPA criteria where none existed previously; the criteria for GPA and MPA now specifically differentiate each other, with more differences between them in the frequencies of clinical features. Our findings support the preferential use of ACR/EULAR over Ankara criteria for GPA in pediatrics. (Figure presented.).
AB - Objective: To assess the 2022 American College of Rheumatology (ACR)/EULAR classification criteria for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) in children with chronic small-to-medium vessel vasculitis. Methods: A cohort of 574 patients, identified by physician's diagnosis (MD-diagnosis) in A Registry of Childhood Vasculitis, was classified by computation of registry data as having granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or eosinophilic GPA after applying (1) ACR/EULAR AAV criteria and (2) pediatric-adapted European Medicines Agency (Ped-EMA) classification algorithm (incorporating Ankara GPA criteria). Venn diagrams compared the resulting GPA and MPA cohorts with MD-diagnosis. Sensitivity and specificity of criteria for GPA were evaluated against MD-diagnosis. Fisher exact test evaluated differences in the frequencies of individual clinical features in GPA versus MPA. Results: Comparing ACR/EULAR criteria against the Ped-EMA algorithm for classifying AAV, more patients were classified as GPA or MPA (n = 396 vs 360, respectively), fewer had GPA (n = 261 vs 288, respectively), more had MPA (n = 135 vs 72, respectively), and fewer GPA cases coclassified as MPA (12% vs 28%, respectively); there were more differences between GPA and MPA in Pediatric Vasculitis Activity Score–defined clinical features (n = 14 vs 10, respectively). When classifying GPA by ACR/EULAR or Ankara criteria, sensitivity (74.5% vs 72.1%, respectively) was comparable, and specificity for ACR/EULAR criteria (93.9% vs 79.9%, respectively) was improved. Conclusion: The 2022 ACR/EULAR classification criteria for AAV perform at least as well as previous pediatric criteria and provide categorical MPA criteria where none existed previously; the criteria for GPA and MPA now specifically differentiate each other, with more differences between them in the frequencies of clinical features. Our findings support the preferential use of ACR/EULAR over Ankara criteria for GPA in pediatrics. (Figure presented.).
UR - https://www.scopus.com/pages/publications/105040695774
U2 - 10.1002/art.70172
DO - 10.1002/art.70172
M3 - Article
C2 - 41958151
AN - SCOPUS:105040695774
SN - 2326-5191
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
ER -